Fig. 2.
Fig. 2. EFS probability of 303 patients with HD according to sCD30 serum levels and stage at diagnosis. 1, sCD30 <100 U/mL and stages I-II; 2, sCD30 <100 U/mL and stages III-IV; 3, sCD30 ≥100 U/mL and stages I-II; and 4, sCD30 ≥100 U/mL and stages III-IV. 1v 2, P = not significant; 2 v 3, P= not significant; 1 v 3, P = .04; 3 v 4,P = .05. Tick marks indicate last follow-up.

EFS probability of 303 patients with HD according to sCD30 serum levels and stage at diagnosis. 1, sCD30 <100 U/mL and stages I-II; 2, sCD30 <100 U/mL and stages III-IV; 3, sCD30 ≥100 U/mL and stages I-II; and 4, sCD30 ≥100 U/mL and stages III-IV. 1v 2, P = not significant; 2 v 3, P= not significant; 1 v 3, P = .04; 3 v 4,P = .05. Tick marks indicate last follow-up.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal